in 1973. It would make sense that if the SIMA were good, BIMA would be better. Indeed, Lytle et al 4 reported from the Cleveland Clinic that patients who received CABG with BIMA grafts did better than if they received a SIMA graft. Since this publication, many studies have demonstrated what seems to be common sense, that patients who receive BIMA grafts 5, 6 or multiple arterial grafts of other types should do much better in the long run. However, patients generally receive BIMA CABG if they are young, are in otherwise good health, and are expected to live a long time. Nearly all studies comparing BIMA with SIMA have been unmatched or propensity-matched studies, with 1 exception. 7 Although propensity-matched retrospective studies provide important information when prospective randomized trials are not available, they remain limited. The study at hand is no exception.
The study by Iribarne et al examined patients from a cohort of 47 984 individuals undergoing CABG in northern New England between 1992 and 2014. From these, 1482 patients with BIMA and the same number of patients with SIMA grafts were compared after a mean of 12 years. The authors reported a greater freedom from repeat revascularization among patients with BIMA compared with those with SIMA grafts (hazard ratio [HR], 0.78; P=0.009). Among the matched cohort, 19% of patients with SIMA grafts underwent repeat revascularization, whereas 15% among patients with BIMA grafts (P=0.004) required reintervention. This may explain the better survival at 12 years in the BIMA group (HR, 0.70; P<0.001). Although the differential rate of revascularization is significant, it represents only a 4% overall difference between groups. As expected, the vast majority (94%) of repeat revascularization procedures were percutaneous coronary intervention in both groups.
Unfortunately, selection bias may have played a role in the different outcomes between patients with BIMA and those with SIMA grafts. The unadjusted in-hospital mortality rate was more than double in the SIMA group versus the BIMA group,
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as was the rate of stroke. The postoperative length of stay was also significantly higher in the SIMA group. This suggests that greater consideration for BIMA grafts was given to lower-risk patients. After propensity matching, there was a 50% greater mortality in the SIMA group compared with the BIMA group of patients. Furthermore, and perhaps more important, after propensity matching, a median of 3 bypass grafts were performed in the SIMA group versus 4 grafts in the BIMA group. Thus, it is difficult to separate the role of number of mammary grafts performed from the health and compliance of the patient or the number of total grafts performed. Nonetheless, in this study, patients having undergone SIMA CABG had a considerably higher rate of major adverse cardiovascular events compared with patients in the BIMA cohort, suggesting a mechanism whereby BIMA CABG may be superior.
Propensity matching does not take into account factors that are not analyzed. Whereas the matching in this study was generally good, it did not take into consideration factors that may have a significant impact on patient outcome after CABG. These factors include frailty, quality of bypass targets, quality of vein and arterial conduits, economic status, compliance with medications, and secondary prevention after CABG. These may have been markedly different between the 2 cohorts. These issues can be addressed only in a prospective randomized trial. The only such trial to date has been ART (Arterial Revascularization Trial), recently presented at the 2016 American Heart Association Scientific Sessions and published in The New England Journal of Medicine. 7 In this study, 3102 patients receiving CABG were randomly assigned to undergo SIMA or BIMA coronary grafting in 28 cardiac surgical centers in 7 countries. The primary outcome was death resulting from any cause at 10 years. Of the patients, 1554 were assigned to undergo SIMA and 1548 to undergo BIMA grafting. At the 5-year follow-up, the rate of death was 8.7% in the BIMA group and 8.4% in the SIMA group (P=0.77), and the rate of the composite of death from any cause, myocardial infarction, or stroke was 12.2% and 12.7%, respectively (P=0.69). What was remarkable in the ART trial was that the rate of sternal wound complication was 3.5% in the BIMA group versus 1.9% in the SIMA group (P=0.005), and the rate of sternal reconstruction was 1.9% versus 0.6% (P=0.002). There was no difference in the rate of revascularization, just over 6% in each group. As in the present study by Iribarne et al, there was no difference in outcome at 5 years. It is very possible that at the 10-year follow-up, the outcome curves will diverge in the ART trial. Thus, there is no inconsistency between the ART trial and the study by Iribarne et al. The 10-year results of the ART trial will be presented in the near future and are anxiously awaited.
In summary, the study by Iribarne et al is a well-performed, propensity-matched retrospective analysis of BIMA versus SIMA grafting an average of 12 years after surgery. However, it also demonstrates the limitations of such a study. The findings are similar to other such studies comparing multiple arterial grafting with SIMA CABG. The 10-year results of the ART trial will give us more definitive information on whether BIMA is truly better than SIMA bypass grafting. As with other controversial topics such as off-pump versus on-pump CABG, the role of valve repair versus replacement for ischemic mitral valve insufficiency, and the utility of cell therapy for heart disease, the opinions remain divided. The real improvement observed with BIMA or other methods of multiarterial grafting will be decided only after multiple prospective randomized trials are completed. Even then, opinions may remain divided.
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